Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 2.91
- Piotroski Score 3.00
- Grade Buy
- Symbol (ETON)
- Company Eton Pharmaceuticals, Inc.
- Price $8.42
- Changes Percentage (0.84%)
- Change $0.07
- Day Low $8.26
- Day High $8.52
- Year High $9.12
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; and Rezipres, a ready-to-use formulation of a molecule that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. It also offers Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; EPRONTIA, a liquid formulation of topiramate; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis. In addition, the company develops Zonisamide Oral Suspension for the treatment of partial on-set seizures; Lamotrigine for Oral Suspension for the treatment of partial on-set seizures; cysteine injection; dehydrated alcohol injection; and Zeneo hydrocortisone autoinjector. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/14/2024
- Fiscal Year End N/A
- Average Stock Price Target $13.00
- High Stock Price Target $15.00
- Low Stock Price Target $11.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $0.03
- Trailing P/E Ratio 120.33
- Forward P/E Ratio 120.33
- P/E Growth 120.33
- Net Income $-936,000
Income Statement
Quarterly
Annual
Latest News of ETON
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
John Middleton on Phillies' need for change, the payroll, and 2 stories he'll tell the players
After the Phillies' disappointing postseason exit, owner John Middleton met with president Dave Dombrowski to address necessary changes. The organization is focused on aggressive improvements and sust...
By The New York Times | 11 hours ago -
U.S., Europe investigating devices detonated at air DHL cargo hubs in U.K. and Germany
U.S. and European authorities are investigating incendiary devices detonated at DHL hubs in Germany and the U.K., possibly linked to Russian intelligence. Concerns arise about similar devices being pl...
By CBS News | 13 hours ago -
Jenkins' 19 help Seton Hall defeat Saint Peter's 57-53
Seton Hall defeated Saint Peter's with a 57-53 victory, led by Chaunce Jenkins' 19 points. Jenkins, along with Aligbe and Addae-Wusu, contributed to the win, while Saint Peter's top scorers were Eaton...
By AP NEWS | 16 hours ago
